CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

Overview of attention for article published in Proceedings of the National Academy of Sciences of the United States of America, August 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

news: 1 news outlet
twitter: 8 X users

patent: 12 patents
f1000: 1 research highlight platform

Readers on

mendeley: 198 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 12 patents that reference this research output.

Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP)

Grant US-12454532-B2

United States of America

28 Oct 2025

CBP/P300 DEGRADERS AND THERAPEUTIC USES THEREOF

Application WO-2025160103-A1

World Intellectual Property Organisation (WIPO)

31 Jul 2025

Inhibiting cyclic AMP-responsive element-binding protein (CREB)

Grant US-12351577-B2

United States of America

08 Jul 2025

CREBBP/P300 HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CYTOPENIAS AND THEIR…

Application WO-2025036963-A1

World Intellectual Property Organisation (WIPO)

20 Feb 2025

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 8 additional patents.